| Christina S Manning, MD | |
|
9 Healthcare Drive, Suite 208, Smmc Primecare Pediatrics, Biddeford, ME 04005 | |
| (207) 282-7531 | |
| (207) 286-3787 |
| Full Name | Christina S Manning |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 9 Healthcare Drive, Suite 208, Biddeford, Maine |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598729519 | NPI | - | NPPES |
| 1598729519 | Medicaid | ME | |
| 5680015 | Other | ME | CIGNA |
| 3538761 | Other | ME | AETNA |
| 1598729519 | Other | ME | ANTHEM |
| AA16518 | Other | ME | HARVARD PILGRIM |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | MD16505 (Maine) | Primary |
| Entity Name | Maine Medical Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134144090 PECOS PAC ID: 9335043967 Enrollment ID: O20040331000191 |
News Archive
Although we spend a lot of our time online nowadays-streaming music and video, checking email and social media, or obsessively reading the news-few of us know about the mathematical algorithms that manage how our content is delivered.
Patients with rheumatic conditions are in need of symptom relief and some are turning to herbal cannabis as a treatment option. However, the effectiveness and safety of medical marijuana to treat symptoms of rheumatic conditions such as rheumatoid arthritis, lupus, or fibromyalgia is not supported by medical evidence. A new article published in Arthritis Care & Research, a journal of the American College of Rheumatology, explores the risks associated with using herbal cannabis for medicinal purposes and advises healthcare providers to discourage rheumatology patients from using this drug as therapy.
The decision regarding treatment following breast-conserving surgery for patients diagnosed with ductal carcinoma in-situ (DCIS) has long been an area of discussion and confusion for patients and physicians alike. While the mortality rates for DCIS remain low, the risk of local recurrence in the breast is high. Standard treatments following surgery include radiation therapy and hormone treatment.
Onyx Pharmaceuticals, Inc. today announced updated interim results of the Phase 1b dose-escalation trial, known as the 006 study, evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed and/or refractory myeloma. These data are being presented today at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
› Verified 5 days ago
| Entity Name | Mainehealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790265502 PECOS PAC ID: 7517860588 Enrollment ID: O20040701000166 |
News Archive
Although we spend a lot of our time online nowadays-streaming music and video, checking email and social media, or obsessively reading the news-few of us know about the mathematical algorithms that manage how our content is delivered.
Patients with rheumatic conditions are in need of symptom relief and some are turning to herbal cannabis as a treatment option. However, the effectiveness and safety of medical marijuana to treat symptoms of rheumatic conditions such as rheumatoid arthritis, lupus, or fibromyalgia is not supported by medical evidence. A new article published in Arthritis Care & Research, a journal of the American College of Rheumatology, explores the risks associated with using herbal cannabis for medicinal purposes and advises healthcare providers to discourage rheumatology patients from using this drug as therapy.
The decision regarding treatment following breast-conserving surgery for patients diagnosed with ductal carcinoma in-situ (DCIS) has long been an area of discussion and confusion for patients and physicians alike. While the mortality rates for DCIS remain low, the risk of local recurrence in the breast is high. Standard treatments following surgery include radiation therapy and hormone treatment.
Onyx Pharmaceuticals, Inc. today announced updated interim results of the Phase 1b dose-escalation trial, known as the 006 study, evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed and/or refractory myeloma. These data are being presented today at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
› Verified 5 days ago
| Entity Name | Southern Maine Health Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659392819 PECOS PAC ID: 0143208348 Enrollment ID: O20040713001060 |
News Archive
Although we spend a lot of our time online nowadays-streaming music and video, checking email and social media, or obsessively reading the news-few of us know about the mathematical algorithms that manage how our content is delivered.
Patients with rheumatic conditions are in need of symptom relief and some are turning to herbal cannabis as a treatment option. However, the effectiveness and safety of medical marijuana to treat symptoms of rheumatic conditions such as rheumatoid arthritis, lupus, or fibromyalgia is not supported by medical evidence. A new article published in Arthritis Care & Research, a journal of the American College of Rheumatology, explores the risks associated with using herbal cannabis for medicinal purposes and advises healthcare providers to discourage rheumatology patients from using this drug as therapy.
The decision regarding treatment following breast-conserving surgery for patients diagnosed with ductal carcinoma in-situ (DCIS) has long been an area of discussion and confusion for patients and physicians alike. While the mortality rates for DCIS remain low, the risk of local recurrence in the breast is high. Standard treatments following surgery include radiation therapy and hormone treatment.
Onyx Pharmaceuticals, Inc. today announced updated interim results of the Phase 1b dose-escalation trial, known as the 006 study, evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed and/or refractory myeloma. These data are being presented today at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christina S Manning, MD P.o. Box 626, Smmc Primecare Physicians, Bidddeford, ME 04005 Ph: (207) 282-9080 | Christina S Manning, MD 9 Healthcare Drive, Suite 208, Smmc Primecare Pediatrics, Biddeford, ME 04005 Ph: (207) 282-7531 |
News Archive
Although we spend a lot of our time online nowadays-streaming music and video, checking email and social media, or obsessively reading the news-few of us know about the mathematical algorithms that manage how our content is delivered.
Patients with rheumatic conditions are in need of symptom relief and some are turning to herbal cannabis as a treatment option. However, the effectiveness and safety of medical marijuana to treat symptoms of rheumatic conditions such as rheumatoid arthritis, lupus, or fibromyalgia is not supported by medical evidence. A new article published in Arthritis Care & Research, a journal of the American College of Rheumatology, explores the risks associated with using herbal cannabis for medicinal purposes and advises healthcare providers to discourage rheumatology patients from using this drug as therapy.
The decision regarding treatment following breast-conserving surgery for patients diagnosed with ductal carcinoma in-situ (DCIS) has long been an area of discussion and confusion for patients and physicians alike. While the mortality rates for DCIS remain low, the risk of local recurrence in the breast is high. Standard treatments following surgery include radiation therapy and hormone treatment.
Onyx Pharmaceuticals, Inc. today announced updated interim results of the Phase 1b dose-escalation trial, known as the 006 study, evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed and/or refractory myeloma. These data are being presented today at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
› Verified 5 days ago
Katherine E Harrod, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 9 Healthcare Drive, Suite 208, Biddeford, ME 04005 Phone: 207-282-7531 Fax: 207-286-3787 | |
Katherine K. Yanagisawa, D.O. Pediatrics Medicare: Medicare Enrolled Practice Location: 9 Healthcare Dr, Biddeford, ME 04005 Phone: 207-282-7531 | |
Margaret A Bordeau, D.O. Pediatrics Medicare: Medicare Enrolled Practice Location: 1 Medical Center Dr, Biddeford, ME 04005 Phone: 207-283-7000 Fax: 207-286-3787 | |
Dr. Cynthia A Patraitis, DO Pediatrics Medicare: Medicare Enrolled Practice Location: 9 Healthcare Dr, Suite 208, Biddeford, ME 04005 Phone: 207-282-7531 Fax: 207-286-3787 | |
Joan D Pelletier, D.O. Pediatrics Medicare: Medicare Enrolled Practice Location: 9 Healthcare Drive, Suite 208, Biddeford, ME 04005 Phone: 207-282-7531 Fax: 207-286-3787 |